← FDA DRUG APPROVALS

FDA ANDA · ANDA075696

ETODOLAC

Sponsor: ACTAVIS ELIZABETH

APPLICATION
ANDA075696
TYPE
ANDA
ORIGINAL APPROVAL
2000-07-31
LATEST ACTION
2024-11-21
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

ETODOLACDiscontinued
ETODOLAC 400MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2024-11-21Labeling · Supplement 17 · standardAP
2021-04-28Labeling · Supplement 16 · standardAP
2016-05-09Labeling · Supplement 15 · standardAP
2016-02-05Labeling · Supplement 14 · standardAP
2004-09-23Labeling · Supplement 10AP
2001-11-02Manufacturing (CMC) · Supplement 4AP
2001-10-05Manufacturing (CMC) · Supplement 2AP
2001-05-07Manufacturing (CMC) · Supplement 1AP
2000-07-31OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →